The road to health technology assessment (HTA) has taken different paths in the Asia Pacific (APAC) region. Join us for insights and key lessons learned when engaging with the developing HTA processes in China and Japan.
Since 2017, China has made substantial changes to the market access process, including the introduction of price negotiation and the use of health economics to evaluate the value of new medicines. With HTA involvement in the reimbursement process, there are new challenges for pharmaceutical companies in gathering local data and using health economic modeling to provide economic value evidence. Using the right set of pricing and market access strategies will help manufacturers in achieving inclusion in the Chinese National Reimbursement Drug List (NRDL).
In 2019, Japan’s Ministry of Health, Labour and Welfare (MHLW) launched a formal HTA process for new drugs following a two-year pilot cost-effectiveness assessment (CEA) process for existing drugs and medical devices with the highest premiums. Decisions arising from the pilot were the use of CEA solely for price adjustment (not reimbursement) as well as factors for selecting products for appraisal.
Join this webinar to learn the process and challenges to get on the NRDL in China or with undergoing price adjustment review with the MHLW in Japan, including:
- Current HTA submission guidelines
- Recent changes and challenges in market access process
- Use of health economic modeling to generate value evidence package
- Lessons learned impacting a positive process
Click here for additional information and registration details.
